The treatment of depression — searching for new ideas
Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.988648/full |
| _version_ | 1798021172056555520 |
|---|---|
| author | Katarzyna Stachowicz Magdalena Sowa-Kućma Magdalena Sowa-Kućma |
| author_facet | Katarzyna Stachowicz Magdalena Sowa-Kućma Magdalena Sowa-Kućma |
| author_sort | Katarzyna Stachowicz |
| collection | DOAJ |
| description | Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frontline pharmacological strategies for the medical treatment of depression. In addition, approved by FDA in 2019, esketamine [as nasal spray; N-methyl-D-aspartate (NMDA) receptors antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, L-type voltage-dependent calcium channel (L-VDCC), opioid receptors, and monoaminergic receptors] is an essential compound in suicide and drug-resistant depression. However, the treatment of depression is burdened with severe side effects, and in many cases, it is ineffective. An equally important issue is the choice of antidepressant therapy in people with comorbid somatic diseases, for example, due to possible interactions with the patient's other drugs. Therefore, there is a great need for new antidepressants with different mechanisms of action and the need to refine the search for new substances. The purpose of this review was to discuss new research directions and new trends that dominate laboratories worldwide. We have reviewed the literature to present new points on the pharmacological target of substances with antidepressant activity. In addition, we propose a new perspective on depressive therapies. |
| first_indexed | 2024-04-11T17:09:29Z |
| format | Article |
| id | doaj.art-bc4272596308445a91324d7efd8e91f7 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T17:09:29Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-bc4272596308445a91324d7efd8e91f72022-12-22T04:12:57ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.988648988648The treatment of depression — searching for new ideasKatarzyna Stachowicz0Magdalena Sowa-Kućma1Magdalena Sowa-Kućma2Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, PolandDepartment of Human Physiology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, PolandCentre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszow University, Rzeszow, PolandDepression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frontline pharmacological strategies for the medical treatment of depression. In addition, approved by FDA in 2019, esketamine [as nasal spray; N-methyl-D-aspartate (NMDA) receptors antagonist with additional effects on α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, L-type voltage-dependent calcium channel (L-VDCC), opioid receptors, and monoaminergic receptors] is an essential compound in suicide and drug-resistant depression. However, the treatment of depression is burdened with severe side effects, and in many cases, it is ineffective. An equally important issue is the choice of antidepressant therapy in people with comorbid somatic diseases, for example, due to possible interactions with the patient's other drugs. Therefore, there is a great need for new antidepressants with different mechanisms of action and the need to refine the search for new substances. The purpose of this review was to discuss new research directions and new trends that dominate laboratories worldwide. We have reviewed the literature to present new points on the pharmacological target of substances with antidepressant activity. In addition, we propose a new perspective on depressive therapies.https://www.frontiersin.org/articles/10.3389/fphar.2022.988648/fulldepressionantidepressantsnew targetglutamate receptorsDSCAM |
| spellingShingle | Katarzyna Stachowicz Magdalena Sowa-Kućma Magdalena Sowa-Kućma The treatment of depression — searching for new ideas Frontiers in Pharmacology depression antidepressants new target glutamate receptors DSCAM |
| title | The treatment of depression — searching for new ideas |
| title_full | The treatment of depression — searching for new ideas |
| title_fullStr | The treatment of depression — searching for new ideas |
| title_full_unstemmed | The treatment of depression — searching for new ideas |
| title_short | The treatment of depression — searching for new ideas |
| title_sort | treatment of depression searching for new ideas |
| topic | depression antidepressants new target glutamate receptors DSCAM |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.988648/full |
| work_keys_str_mv | AT katarzynastachowicz thetreatmentofdepressionsearchingfornewideas AT magdalenasowakucma thetreatmentofdepressionsearchingfornewideas AT magdalenasowakucma thetreatmentofdepressionsearchingfornewideas AT katarzynastachowicz treatmentofdepressionsearchingfornewideas AT magdalenasowakucma treatmentofdepressionsearchingfornewideas AT magdalenasowakucma treatmentofdepressionsearchingfornewideas |